BioSpace News Archive

Bausch Health Companies Inc. today announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.

Fluidx Medical disclosed study results examining extent of vessel filling using the GPX Embolic Device compared to microspheres, a common treatment for many types of tumors.

Gamida Cell Ltd. announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).

Promore Pharma have announced today that the company has received a granted patent in the European Union for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds.

Adicet Bio, Inc. today reported financial results and operational highlights for the second quarter ended June 30, 2022.

Dyne Therapeutics, Inc. today announced the publication of Duchenne muscular dystrophy (DMD) preclinical data in a “Breakthrough Article” in Nucleic Acids Research, an honor reserved for approximately two percent of its accepted articles.

BrainsWay Ltd. today reported second quarter 2022 financial results and provided an operational update.

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda.

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of three week safety data from more than 20 patients enrolled into the trial as of June 30, 2022.

Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients.